{"pmid":32444504,"title":"Challenges in the management of older patients with acute coronary syndromes in the COVID-19 pandemic.","text":["Challenges in the management of older patients with acute coronary syndromes in the COVID-19 pandemic.","Ischaemic heart disease (IHD), in particular acute coronary syndrome (ACS), comprising ST-elevation myocardial infarction, non-ST-elevation myocardial infarction and unstable angina, is the leading cause of death worldwide. Age is a major predictor of adverse outcome following ACS. COVID-19 infection seems to escalate the risk in older patients with heart disease. Increasing odds of in-hospital death is associated with older age following COVID-19 infection. Importantly, it seems older patients with comorbidities such as cardiovascular disease (CVD), in particular IHD, diabetes and hypertension, are at the highest risk of mortality following COVID-19 infection. The evidence is sparse on the optimal care of older patients with ACS with lack of robust randomised controlled trials. In this setting, with the serious threat imposed by the COVID-19 pandemic in the context of rapidly evolving knowledge with much unknown, it is important to weigh the risks and benefits of treatment strategies offered to older patients. In cases where risks outweigh the benefits, it might not be an unreasonable option to treat such patients with a conservative or a palliative approach. Further evidence to elucidate whether invasive management is beneficial in older patients with ACS is required out-with the COVID-19 pandemic. Though it is hoped that the actual acute phase of COVID-19 infection will be short lived, it is vital that important clinical research is continued, given the long-term benefits of ongoing clinical research for patients with long-term conditions, including CVD. This review aimed to evaluate the challenges and the management strategies in the care of older patients presenting with ACS in the context of the COVID-19 pandemic.","Heart","Rowland, Ben","Kunadian, Vijay","32444504"],"abstract":["Ischaemic heart disease (IHD), in particular acute coronary syndrome (ACS), comprising ST-elevation myocardial infarction, non-ST-elevation myocardial infarction and unstable angina, is the leading cause of death worldwide. Age is a major predictor of adverse outcome following ACS. COVID-19 infection seems to escalate the risk in older patients with heart disease. Increasing odds of in-hospital death is associated with older age following COVID-19 infection. Importantly, it seems older patients with comorbidities such as cardiovascular disease (CVD), in particular IHD, diabetes and hypertension, are at the highest risk of mortality following COVID-19 infection. The evidence is sparse on the optimal care of older patients with ACS with lack of robust randomised controlled trials. In this setting, with the serious threat imposed by the COVID-19 pandemic in the context of rapidly evolving knowledge with much unknown, it is important to weigh the risks and benefits of treatment strategies offered to older patients. In cases where risks outweigh the benefits, it might not be an unreasonable option to treat such patients with a conservative or a palliative approach. Further evidence to elucidate whether invasive management is beneficial in older patients with ACS is required out-with the COVID-19 pandemic. Though it is hoped that the actual acute phase of COVID-19 infection will be short lived, it is vital that important clinical research is continued, given the long-term benefits of ongoing clinical research for patients with long-term conditions, including CVD. This review aimed to evaluate the challenges and the management strategies in the care of older patients presenting with ACS in the context of the COVID-19 pandemic."],"journal":"Heart","authors":["Rowland, Ben","Kunadian, Vijay"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32444504","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/heartjnl-2020-317011","keywords":["acute coronary syndromes","cardiac catheterisation and angiography","coronary artery disease"],"topics":["Prevention"],"weight":1,"_version_":1667600475899297792,"score":9.490897,"similar":[{"pmid":32498230,"title":"Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties.","text":["Acute Coronary Syndromes and Covid-19: Exploring the Uncertainties.","Since an association between myocardial infarction (MI) and respiratory infections has been described for influenza viruses and other respiratory viral agents, understanding possible physiopathological links between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and acute coronary syndromes (ACS) is of the greatest importance. The initial data suggest an underestimation of ACS cases all over the world, but acute MI still represents a major cause of morbidity and mortality worldwide and should not be overshadowed during the coronavirus disease (Covid-19) pandemic. No common consensus regarding the most adequate healthcare management policy for ACS is currently available. Indeed, important differences have been reported between the measures employed to treat ACS in China during the first disease outbreak and what currently represents clinical practice across Europe and the USA. This review aims to discuss the pathophysiological links between MI, respiratory infections, and Covid-19; epidemiological data related to ACS at the time of the Covid-19 pandemic; and learnings that have emerged so far from several catheterization labs and coronary care units all over the world, in order to shed some light on the current strategies for optimal management of ACS patients with confirmed or suspected SARS-CoV-2 infection.","J Clin Med","Schiavone, Marco","Gobbi, Cecilia","Biondi-Zoccai, Giuseppe","D'Ascenzo, Fabrizio","Palazzuoli, Alberto","Gasperetti, Alessio","Mitacchione, Gianfranco","Viecca, Maurizio","Galli, Massimo","Fedele, Francesco","Mancone, Massimo","Forleo, Giovanni Battista","32498230"],"abstract":["Since an association between myocardial infarction (MI) and respiratory infections has been described for influenza viruses and other respiratory viral agents, understanding possible physiopathological links between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and acute coronary syndromes (ACS) is of the greatest importance. The initial data suggest an underestimation of ACS cases all over the world, but acute MI still represents a major cause of morbidity and mortality worldwide and should not be overshadowed during the coronavirus disease (Covid-19) pandemic. No common consensus regarding the most adequate healthcare management policy for ACS is currently available. Indeed, important differences have been reported between the measures employed to treat ACS in China during the first disease outbreak and what currently represents clinical practice across Europe and the USA. This review aims to discuss the pathophysiological links between MI, respiratory infections, and Covid-19; epidemiological data related to ACS at the time of the Covid-19 pandemic; and learnings that have emerged so far from several catheterization labs and coronary care units all over the world, in order to shed some light on the current strategies for optimal management of ACS patients with confirmed or suspected SARS-CoV-2 infection."],"journal":"J Clin Med","authors":["Schiavone, Marco","Gobbi, Cecilia","Biondi-Zoccai, Giuseppe","D'Ascenzo, Fabrizio","Palazzuoli, Alberto","Gasperetti, Alessio","Mitacchione, Gianfranco","Viecca, Maurizio","Galli, Massimo","Fedele, Francesco","Mancone, Massimo","Forleo, Giovanni Battista"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32498230","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3390/jcm9061683","keywords":["covid-19","stemi","acute coronary syndromes","drug treatment","infectious disease","myocardial infarction","pathophysiology","percutaneous coronary intervention","respiratory infections","thrombolysis"],"locations":["China","USA","optimal"],"countries":["China","United States"],"countries_codes":["CHN|China","USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1668890966454435842,"score":335.79785},{"pmid":32405641,"title":"EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic.","text":["EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic.","The coronavirus disease 2019 (COVID-19) pandemic poses an unprecedented challenge to healthcare worldwide. The infection can be life threatening and require intensive care treatment. The transmission of the disease poses a risk to both patients and healthcare workers. The number of patients requiring hospital admission and intensive care may overwhelm health systems and negatively affect standard care for patients presenting with conditions needing emergency interventions. This position statements aims to assist cardiologists in the invasive management of acute coronary syndrome (ACS) patients in the context of the COVID-19 pandemic. To that end, we assembled a panel of interventional cardiologists and acute cardiac care specialists appointed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and from the Acute Cardiovascular Care Association (ACVC) and included the experience from the first and worst affected areas in Europe. Modified diagnostic and treatment algorithms are proposed to adapt evidence-based protocols for this unprecedented challenge. Various clinical scenarios, as well as management algorithms for patients with a diagnosed or suspected COVID-19 infection, presenting with ST- and non-ST-segment elevation ACS are described. In addition, we address the need for re-organization of ACS networks, with redistribution of hub and spoke hospitals, as well as for in-hospital reorganization of emergency rooms and cardiac units, with examples coming from multiple European countries. Furthermore, we provide a guidance to reorganization of catheterization laboratories and, importantly, measures for protection of healthcare providers involved with invasive procedures.","Eur Heart J","Chieffo, Alaide","Stefanini, Giulio G","Price, Susanna","Barbato, Emanuele","Tarantini, Giuseppe","Karam, Nicole","Moreno, Raul","Buchanan, Gill Louise","Gilard, Martine","Halvorsen, Sigrun","Huber, Kurt","James, Stefan","Neumann, Franz-Josef","Mollmann, Helge","Roffi, Marco","Tavazzi, Guido","Mauri Ferre, Josepa","Windecker, Stephan","Dudek, Dariusz","Baumbach, Andreas","32405641"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic poses an unprecedented challenge to healthcare worldwide. The infection can be life threatening and require intensive care treatment. The transmission of the disease poses a risk to both patients and healthcare workers. The number of patients requiring hospital admission and intensive care may overwhelm health systems and negatively affect standard care for patients presenting with conditions needing emergency interventions. This position statements aims to assist cardiologists in the invasive management of acute coronary syndrome (ACS) patients in the context of the COVID-19 pandemic. To that end, we assembled a panel of interventional cardiologists and acute cardiac care specialists appointed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and from the Acute Cardiovascular Care Association (ACVC) and included the experience from the first and worst affected areas in Europe. Modified diagnostic and treatment algorithms are proposed to adapt evidence-based protocols for this unprecedented challenge. Various clinical scenarios, as well as management algorithms for patients with a diagnosed or suspected COVID-19 infection, presenting with ST- and non-ST-segment elevation ACS are described. In addition, we address the need for re-organization of ACS networks, with redistribution of hub and spoke hospitals, as well as for in-hospital reorganization of emergency rooms and cardiac units, with examples coming from multiple European countries. Furthermore, we provide a guidance to reorganization of catheterization laboratories and, importantly, measures for protection of healthcare providers involved with invasive procedures."],"journal":"Eur Heart J","authors":["Chieffo, Alaide","Stefanini, Giulio G","Price, Susanna","Barbato, Emanuele","Tarantini, Giuseppe","Karam, Nicole","Moreno, Raul","Buchanan, Gill Louise","Gilard, Martine","Halvorsen, Sigrun","Huber, Kurt","James, Stefan","Neumann, Franz-Josef","Mollmann, Helge","Roffi, Marco","Tavazzi, Guido","Mauri Ferre, Josepa","Windecker, Stephan","Dudek, Dariusz","Baumbach, Andreas"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405641","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/eurheartj/ehaa381","keywords":["acs","covid-19","nstemi","pci","stemi"],"topics":["Prevention"],"weight":1,"_version_":1666802845475667968,"score":272.53482},{"pmid":32404302,"title":"EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic.","text":["EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic.","The coronavirus disease 2019 (COVID-19) pandemic poses an unprecedented challenge to healthcare worldwide. The infection can be life threatening and require intensive care treatment. The transmission of the disease poses a risk to both patients and healthcare workers. The number of patients requiring hospital admission and intensive care may overwhelm health systems and negatively affect standard care for patients presenting with conditions needing emergency interventions. This position statements aims to assist cardiologists in the invasive management of acute coronary syndrome (ACS) patients in the context of the COVID-19 pandemic. To that end, we assembled a panel of interventional cardiologists and acute cardiac care specialists appointed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and from the Acute Cardiovascular Care Association (ACVC) and included the experience from the first and worst affected areas in Europe. Modified diagnostic and treatment algorithms are proposed to adapt evidence-based protocols for this unprecedented challenge. Various clinical scenarios, as well as management algorithms for patients with a diagnosed or suspected COVID-19 infection, presenting with ST- and non-ST-segment elevation ACS are described. In addition, we address the need for re-organization of ACS networks, with redistribution of hub and spoke hospitals, as well as for in-hospital reorganization of emergency rooms and cardiac units, with examples coming from multiple European countries. Furthermore, we provide a guidance to reorganization of catheterization laboratories and, importantly, measures for protection of healthcare providers involved with invasive procedures.","EuroIntervention","Chieffo, Alaide","Stefanini, Giulio G","Price, Susanna","Barbato, Emanuele","Tarantini, Giuseppe","Karam, Nicole","Moreno, Raul","Buchanan, Gill Louise","Gilard, Martine","Halvorsen, Sigrun","Huber, Kurt","James, Stefan","Neumann, Franz-Josef","Mollmann, Helge","Roffi, Marco","Tavazzi, Guido","Ferre, Josepa Mauri","Windecker, Stephan","Dudek, Dariusz","Baumbach, Andreas","32404302"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic poses an unprecedented challenge to healthcare worldwide. The infection can be life threatening and require intensive care treatment. The transmission of the disease poses a risk to both patients and healthcare workers. The number of patients requiring hospital admission and intensive care may overwhelm health systems and negatively affect standard care for patients presenting with conditions needing emergency interventions. This position statements aims to assist cardiologists in the invasive management of acute coronary syndrome (ACS) patients in the context of the COVID-19 pandemic. To that end, we assembled a panel of interventional cardiologists and acute cardiac care specialists appointed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and from the Acute Cardiovascular Care Association (ACVC) and included the experience from the first and worst affected areas in Europe. Modified diagnostic and treatment algorithms are proposed to adapt evidence-based protocols for this unprecedented challenge. Various clinical scenarios, as well as management algorithms for patients with a diagnosed or suspected COVID-19 infection, presenting with ST- and non-ST-segment elevation ACS are described. In addition, we address the need for re-organization of ACS networks, with redistribution of hub and spoke hospitals, as well as for in-hospital reorganization of emergency rooms and cardiac units, with examples coming from multiple European countries. Furthermore, we provide a guidance to reorganization of catheterization laboratories and, importantly, measures for protection of healthcare providers involved with invasive procedures."],"journal":"EuroIntervention","authors":["Chieffo, Alaide","Stefanini, Giulio G","Price, Susanna","Barbato, Emanuele","Tarantini, Giuseppe","Karam, Nicole","Moreno, Raul","Buchanan, Gill Louise","Gilard, Martine","Halvorsen, Sigrun","Huber, Kurt","James, Stefan","Neumann, Franz-Josef","Mollmann, Helge","Roffi, Marco","Tavazzi, Guido","Ferre, Josepa Mauri","Windecker, Stephan","Dudek, Dariusz","Baumbach, Andreas"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404302","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.4244/EIJY20M05_01","topics":["Prevention"],"weight":1,"_version_":1666802845480910848,"score":272.53482},{"pmid":32425198,"pmcid":"PMC7229476","title":"North American COVID-19 ST-segment elevation myocardial infarction (NACMI) registry: Rationale, design, and implications.","text":["North American COVID-19 ST-segment elevation myocardial infarction (NACMI) registry: Rationale, design, and implications.","Background: The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes coronavirus disease 2019 (COVID-19), has resulted in a global pandemic. Patients with cardiovascular risk factors or established cardiovascular disease are more likely to experience severe or critical COVID-19 illness and myocardial injury is a key extra-pulmonary manifestation. These patients frequently present with ST-elevation on an electrocardiogram (ECG) due to multiple etiologies including obstructive, non-obstructive, and/or angiographically normal coronary arteries. The incidence of ST-elevation myocardial infarction (STEMI) mimics in COVID-19 positive hospitalized patients, and the association with morbidity and mortality is unknown. Understanding the natural history and appropriate management of COVID-19 patients presenting with ST elevation is essential to inform patient management decisions and protect healthcare workers. Methods: The Society for Cardiovascular Angiography and Interventions (SCAI) and The Canadian Association of Interventional Cardiology (CAIC) in conjunction with the American College of Cardiology Interventional Council have collaborated to create a multi-center observational registry, North American COVID-19 ST-Segment Elevation Myocardial Infarction (NACMI). This registry will enroll confirmed COVID-19 patients and persons under investigation (PUI) with new ST-segment elevation or new onset left bundle branch block (LBBB) on the ECG with clinical suspicion of myocardial ischemia. We will compare demographics, clinical findings, outcomes and management of these patients with a historical control group of over 15,000 consecutive STEMI activation patients from the Midwest STEMI Consortium using propensity matching. The primary clinical outcome will be in- hospital major adverse cardiovascular events (MACE) defined as composite of all-cause mortality, stroke, recurrent MI, and repeat unplanned revascularization in COVID-19 confirmed or PUI. Secondary outcomes will include the following: reporting of etiologies of ST Elevation; cardiovascular mortality due to myocardial infarction, cardiac arrest and /or shock; individual components of the primary outcome; composite primary outcome at one year; as well as ECG and angiographic characteristics. Conclusion: The multicenter NACMI registry will collect data regarding ST elevation on ECG in COVID-19 patients to determine the etiology and associated clinical outcomes. The collaboration and speed with which this registry has been created, refined, and promoted serves as a template for future research endeavors.","Am Heart J","Dehghani, Payam","Davidson, Laura J","Grines, Cindy L","Nayak, Keshav","Saw, Jackie","Kaul, Prashant","Bagai, Akshay","Garberich, Ross","Schmidt, Christian","Ly Md Sm, Hung Q","Giri, Jay","Meraj, Perwaiz","Shah, Binita","Garcia, Santiago","Sharkey, Scott","Wood, David A","Welt, Frederick G","Mahmud, Ehtisham M","Henry, Timothy D","32425198"],"abstract":["Background: The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes coronavirus disease 2019 (COVID-19), has resulted in a global pandemic. Patients with cardiovascular risk factors or established cardiovascular disease are more likely to experience severe or critical COVID-19 illness and myocardial injury is a key extra-pulmonary manifestation. These patients frequently present with ST-elevation on an electrocardiogram (ECG) due to multiple etiologies including obstructive, non-obstructive, and/or angiographically normal coronary arteries. The incidence of ST-elevation myocardial infarction (STEMI) mimics in COVID-19 positive hospitalized patients, and the association with morbidity and mortality is unknown. Understanding the natural history and appropriate management of COVID-19 patients presenting with ST elevation is essential to inform patient management decisions and protect healthcare workers. Methods: The Society for Cardiovascular Angiography and Interventions (SCAI) and The Canadian Association of Interventional Cardiology (CAIC) in conjunction with the American College of Cardiology Interventional Council have collaborated to create a multi-center observational registry, North American COVID-19 ST-Segment Elevation Myocardial Infarction (NACMI). This registry will enroll confirmed COVID-19 patients and persons under investigation (PUI) with new ST-segment elevation or new onset left bundle branch block (LBBB) on the ECG with clinical suspicion of myocardial ischemia. We will compare demographics, clinical findings, outcomes and management of these patients with a historical control group of over 15,000 consecutive STEMI activation patients from the Midwest STEMI Consortium using propensity matching. The primary clinical outcome will be in- hospital major adverse cardiovascular events (MACE) defined as composite of all-cause mortality, stroke, recurrent MI, and repeat unplanned revascularization in COVID-19 confirmed or PUI. Secondary outcomes will include the following: reporting of etiologies of ST Elevation; cardiovascular mortality due to myocardial infarction, cardiac arrest and /or shock; individual components of the primary outcome; composite primary outcome at one year; as well as ECG and angiographic characteristics. Conclusion: The multicenter NACMI registry will collect data regarding ST elevation on ECG in COVID-19 patients to determine the etiology and associated clinical outcomes. The collaboration and speed with which this registry has been created, refined, and promoted serves as a template for future research endeavors."],"journal":"Am Heart J","authors":["Dehghani, Payam","Davidson, Laura J","Grines, Cindy L","Nayak, Keshav","Saw, Jackie","Kaul, Prashant","Bagai, Akshay","Garberich, Ross","Schmidt, Christian","Ly Md Sm, Hung Q","Giri, Jay","Meraj, Perwaiz","Shah, Binita","Garcia, Santiago","Sharkey, Scott","Wood, David A","Welt, Frederick G","Mahmud, Ehtisham M","Henry, Timothy D"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425198","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ahj.2020.05.006","locations":["North American","North American"],"topics":["Treatment"],"weight":1,"_version_":1667252837717901312,"score":264.05606},{"pmid":32419177,"title":"Collateral damage of COVID-19 pandemic: Delayed medical care.","text":["Collateral damage of COVID-19 pandemic: Delayed medical care.","During the COVID-19 pandemic, emergency room visits have drastically decreased for non-COVID conditions such as appendicitis, heart attack, and stroke. Patients may be avoiding seeking medical attention for fear of catching the deadly condition or as an unintended consequence of stay-at-home orders. This delay in seeking care can lead to increased morbidity and mortality, which has not been figured in the assessment of the extent of damage caused by this pandemic. This case illustrates an example of \"collateral damage\" caused by the COVID-19 pandemic. What would have been a standard ST-elevation myocardial infarction treated with timely and successful stenting of a dominant right coronary artery occlusion, became a much more dangerous postinfarction ventricular septal defect; all because of a 2-day delay in seeking medical attention by an unsuspecting patient.","J Card Surg","Masroor, Saqib","32419177"],"abstract":["During the COVID-19 pandemic, emergency room visits have drastically decreased for non-COVID conditions such as appendicitis, heart attack, and stroke. Patients may be avoiding seeking medical attention for fear of catching the deadly condition or as an unintended consequence of stay-at-home orders. This delay in seeking care can lead to increased morbidity and mortality, which has not been figured in the assessment of the extent of damage caused by this pandemic. This case illustrates an example of \"collateral damage\" caused by the COVID-19 pandemic. What would have been a standard ST-elevation myocardial infarction treated with timely and successful stenting of a dominant right coronary artery occlusion, became a much more dangerous postinfarction ventricular septal defect; all because of a 2-day delay in seeking medical attention by an unsuspecting patient."],"journal":"J Card Surg","authors":["Masroor, Saqib"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419177","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/jocs.14638","keywords":["covid-19","coronary artery disease","postinfarction ventricular septal defect"],"topics":["Case Report"],"weight":1,"_version_":1667159284480212992,"score":263.3574}]}